Clinical Trials Browser

Phase 2 × Has announcements × Plasma cell × Clear all

NCT04634552 2026-03-17

MonumenTAL-1

Phase 2 Recruiting

510 enrolled 1 FDA

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

NCT04649359 2025-12-02

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

Phase 2 Active not recruiting

187 enrolled 14 charts 1 FDA

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03525678 2025-09-03

A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody

Phase 2 Completed

221 enrolled 61 charts 2 FDA

Multiple Myeloma

NCT03361748 2025-05-23

KarMMa

Phase 2 Completed

149 enrolled 29 charts 1 FDA

Multiple Myeloma, Recurrence

NCT03412565 2025-04-29

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

Phase 2 Completed

265 enrolled 21 charts 3 FDA

Multiple Myeloma

NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Phase 2 Completed

206 enrolled 40 charts 2 FDA

CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

NCT02336815 2023-01-26

STORM

Phase 2 Completed

202 enrolled 30 charts 1 FDA

Multiple Myeloma

NCT02963493 2022-11-22

HORIZON

Phase 2 Completed

157 enrolled 26 charts 1 FDA

Multiple Myeloma